| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 984.81 | 46.1% |
| Total Income | 1.0K | 45.1% |
| Expenditure | 848.16 | 46.9% |
| PBT | 169.14 | 34.0% |
| Net Profit | 142.80 | 29.9% |
| OPM | 21.86% | 5.28pp |
| NPM | 14.04% | 3.06pp |
| EPS | 15.83 | 29.9% |
Sharda Cropchem Q1 FY26: Volume Driven Growth, Gross Profit Margin at 35.5%, Aims to Grow Topline by ~15%
25 Jul 2025 · 25 Jul 2025, 01:35 pm
Summary
Sharda Cropchem Limited, one of the leading players in the generic crop protection chemicals industry, has announced its unaudited financial results for the quarter ended 30th June 2025. The company reported a revenue of Rs. 984.8 crores, a YoY increase of 25%. The gross profit margin stood at 35.5%, a YoY increase of 630 basis points. The company aims to grow its topline by ~15% in FY26.
Key Highlights
- 1
Volume driven growth complemented by gradual recovery in prices
- 2
Ongoing focus on product registrations
- 3
Overall Volumes have increased by 13.2% Y-o-Y in Q1 FY26
- 4
Agrochemical volumes grew by 11.4% & Non-Agrochemical volumes grew by 59%
- 5
Capex in Q1 FY26 stands at Rs. 114 crores
- 6
Product Registrations stand at 2,981 with 1,021 applications pending at various stages as on 30th June 2025
- 7
The Company remains Debt free with cash, bank and liquid investments of Rs. 791 crores
Management Comments
Mr. Ramprakash Bubna
Chairman and MD
In Q1 FY26, we recorded strong volume growth of ~13%, with revenues rising ~25% YoY to Rs. 985 crores. This performance was driven by a global demand revival and improved pricing. Europe remains a key contributor in both volume and value terms. With input costs stabilizing, our Gross Margins has expanded by 630 basis points to 35.5% and we expect GP Margins to remain in a similar range going ahead. EBITDA has grown by 67% to Rs. 142 crores with EBITDA Margins at 14.4%. We remain focused on increasing our product registrations in FY26, with planned capex of ~Rs. 400-450 crores. Our strong pipeline of registrations reflects both our resilience and unwavering commitment to growth, laying a strong foundation for sustained future progress. For FY26, we aim to grow our topline by ~15% while maintaining healthy EBITDA Margins in the range of 15-18%.
Informational and educational content only. Not investment advice.